DEA Rescheduling Hearing Ends: What Happens Next
Photo by Zulfugar Karimov via Pexels.
After more than two weeks of live testimony inside DEA headquarters in Arlington, Virginia, the formal hearing on whether to move marijuana from Schedule I to Schedule III wrapped on July 15, 2026. Nobody got a ruling on the spot. Chief Administrative Law Judge Derek Julius instead laid out a structured paperwork process, with an August 17 briefing deadline as the next real checkpoint. That's not a letdown so much as how this system is designed to work -- but it does mean the millions of patients and the businesses already restructuring around this decision are stuck waiting a while longer.
The hearing itself, which started June 29, was the most substantial airing of the rescheduling question the DEA has held. And the market has already started pricing in an outcome: two medical marijuana companies uplisted to the New York Stock Exchange after registering with DEA under an interim Schedule III placement that took effect earlier this year. That's a real, concrete signal that investors think this is heading somewhere, even though nothing is final. What's left is a chain of custody for the decision -- Judge Julius writes a recommendation, both sides get a window to file exceptions, and then it lands on the desk of DEA Administrator Terry Cole, who alone has the authority to actually change the schedule.
How the Hearing Got Here
Photo by Zachary Caraway via Pexels.
To understand why this hearing happened at all, you have to go back to December 18, 2025, when President Trump signed an executive order directing a formal review of marijuana's Schedule I status -- the same classification that puts cannabis alongside heroin and LSD as having no accepted medical use. That order set a chain of events in motion that moved faster than most people expected from a federal bureaucracy. By April 2026, Acting Attorney General Todd Blanche had taken two actions: he placed FDA-approved and state-licensed medical marijuana into Schedule III on an interim basis, and he ordered DEA to hold an expedited hearing on the broader question of rescheduling marijuana generally.
That hearing ran from June 29 to July 15, 2026, entirely at DEA headquarters, with more than two weeks of live witness testimony -- an unusually long proceeding by administrative hearing standards. What made the lineup notable was who actually got a seat at the table as a formal, designated participant. Only rescheduling opponents were granted that status: Smart Approaches to Marijuana, the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, DUID Victim Voices, individual objectors Kenneth Finn and Phillip A. Drum, and the states of Idaho, Indiana, and Nebraska.
That set up a genuinely odd dynamic. With no pro-rescheduling advocacy groups designated as parties, it fell to DEA's own officials to argue in favor of the agency's proposed rule -- meaning DEA effectively defended its own regulatory action against a slate of outside challengers trying to tear it down. It's not the adversarial matchup most observers expected, but it's the one the process produced.
What Judge Julius Actually Ordered
Photo by Sora Shimazaki via Pexels.
Because the in-person hearing days didn't include time allotted for closing arguments, Judge Julius is handling that piece through written submissions instead. Post-hearing briefs are due August 17, 2026, capped at 50 pages each, and parties can use them not just for closing arguments but to flag other issues that came up during testimony that they think deserve more attention in the record. It's a fairly generous page limit for an administrative proceeding, which suggests Julius expects both sides to make detailed, substantive arguments rather than short summaries.
Each designated party gets exactly one brief -- no serial filings, no supplemental rounds unless Julius decides otherwise later. That same August 17 date also serves as the deadline for proposed corrections to the hearing transcript. Once those corrections come in, Julius will issue a final, corrected transcript that gets posted to DEA's website, giving the public an official record of everything that was said over those two-plus weeks.
Once the briefs and transcript corrections are in hand, Julius said he'll write his own recommendation on whether marijuana should move to Schedule III. He didn't offer a timeline for when that recommendation might land, and he was careful to underscore something that matters a lot here: his job is to recommend, not decide. The actual authority to reschedule marijuana rests with the DEA administrator, not with the administrative law judge overseeing the hearing. That distinction is easy to gloss over in casual coverage of this story, but it's the entire structure of what happens next.
The Road From Recommendation to Final Rule
Photo by Laura Musikanski via Pexels.
Once Julius's recommendation is issued, the parties who participated in the hearing get 20 days to file exceptions -- essentially formal objections to whatever he concludes -- before the record is considered complete and ready to move forward. That's a meaningful window built into the process specifically so that the losing side, whichever way Julius leans, has a documented chance to push back before anyone with final authority weighs in.
After exceptions are resolved, the full record -- testimony, exhibits, briefs, Julius's recommendation, and any exceptions filed against it -- goes to DEA Administrator Terry Cole. Cole is the one person in this entire process with actual decision-making power over whether marijuana gets moved to Schedule III. Everything before this point, no matter how extensive, is technically advisory to that final call.
Nobody has offered a firm timeline for either Julius's recommendation or Cole's eventual ruling, which means people expecting resolution before the end of 2026 should probably recalibrate. Given the pace of similar federal rulemaking processes, this could realistically stretch well into 2027 before there's a final rule on the books.
Adding another layer of uncertainty, a congressional committee recently voted to block further steps toward rescheduling, though most lawmakers who've commented on it don't expect that measure to actually become law. It's worth remembering, too, that the current Schedule III placement is narrow by design -- it applies only to FDA-approved and state-licensed medical marijuana operators, not to the broader cannabis market including recreational and unlicensed operations.
Notable Testimony That Shaped the Record
Photo by khezez | خزاز via Pexels.
The testimony that filled those two-plus weeks came from a genuinely wide range of witnesses, which gives Julius a substantial record to draw on beyond the written filings alone. An FDA scientist walked through the medical evidence base supporting rescheduling, addressing the scientific standard the agency has to weigh -- whether marijuana has an accepted medical use and an acceptable safety profile relative to its abuse potential.
A physician from New Hampshire offered clinical testimony grounded in direct patient experience, describing marijuana's medical benefits for the people he treats -- the kind of on-the-ground perspective that tends to carry weight in these proceedings precisely because it isn't abstract.
Perhaps the most unexpected moment came from Humboldt County, California Sheriff William Honsal, who testified on behalf of the opposing states even though his testimony leaned notably favorable toward regulated cannabis markets. That's not a small detail. Having a law enforcement witness called by the anti-rescheduling side end up offering testimony that cuts against the expected narrative says something real about how this issue actually breaks down among people who deal with cannabis policy on the ground, as opposed to how it's often framed in political shorthand.
Taken together, the record Julius has to work with isn't a simple binary of doctors versus cops or scientists versus skeptics. It's messier and more nuanced than that, which is arguably exactly what a hearing like this is supposed to produce.
Why Businesses and Patients Are Already Reacting
Photo by Erik Mclean via Pexels.
The clearest sign that this process is already reshaping the industry, even before any final ruling, is what's happened in the stock market. Trulieve Cannabis Corp. and Glass House Brands have both uplisted to the New York Stock Exchange after registering with DEA under the interim Schedule III framework for medical marijuana. That's a significant institutional milestone for companies that have spent years trading on smaller exchanges or over-the-counter markets due to marijuana's federal status.
The practical upside of Schedule III status for medical operators is concrete: it can ease certain research restrictions on marijuana and improve tax treatment for companies currently squeezed by IRS code 280E, which bars businesses trafficking in Schedule I or II substances from deducting standard business expenses. For medical marijuana companies that qualify under the interim placement, that tax relief alone can meaningfully change their bottom line.
But it's important not to overstate what's actually changed. Recreational markets and unlicensed operators remain entirely untouched by this interim placement -- the current shift applies narrowly to FDA-approved and state-licensed medical marijuana. Nothing here alters the patchwork of state cannabis laws that still governs day-to-day legality for most consumers and businesses. Readers should check their own state's current cannabis laws directly rather than assume federal rescheduling has changed anything locally, since it hasn't -- not yet, and not for the broader market.
Still, the stock market reaction tells you where smart money thinks this is heading. Investors are clearly betting on a broader rescheduling outcome down the line, even with Cole's final decision still an open question with no set date attached to it.
Wrapping up the hearing doesn't resolve anything by itself -- it just shifts the fight from a courtroom-style proceeding with live witnesses into a paperwork phase governed by page limits and filing deadlines. That's a meaningful transition, but it's not a decision. The actual power to reschedule marijuana still sits with one person, DEA Administrator Terry Cole, and nothing that's happened so far binds him to any particular outcome.
Given that neither Julius's recommendation nor Cole's eventual ruling comes with a stated deadline, it's reasonable to expect this story to stay unresolved well past 2026, likely bleeding into 2027 before there's anything resembling a final rule. Federal rulemaking on a substance this politically charged rarely moves on anyone's preferred schedule, and there's no indication this case will be the exception.
The practical thing to watch next isn't a ruling -- it's the paperwork itself. The August 17 briefs, capped at 50 pages per party, will show how strong each side's legal arguments actually are once they're stripped of live-testimony theatrics and boiled down to their sharpest form. The exceptions period that follows Julius's eventual recommendation will do something similar, revealing exactly where the losing side thinks the reasoning fell apart. Read together, those two filings will probably tell you more about which way this is likely to break than anything said aloud during those two weeks in Arlington.